Jim Cramer Nailed These 11 Stock Picks

5. Eli Lilly and Company (NYSE:LLY)

Number of Hedge Fund Holders: 115

Eli Lilly and Company (NYSE:LLY), a pharmaceutical powerhouse, has dominated headlines for its blockbuster GLP-1 weight loss and diabetes treatments. Last year, when the stock briefly dipped, Cramer urged viewers to consider it a buying opportunity.

“Eli Lilly down 20 bucks. Why? The only news is good news; broke ground for a new $2.5 billion plant in Frankfurt, Germany to make Zepbound, their GLP-1 weight loss drug. Call me a buyer if the dust settles.”

Since that segment aired, shares have recovered and risen 7%, validating Cramer’s call and investor confidence in Eli Lilly’s pipeline and growth outlook.

Jim Cramer was asked about Eli Lilly and Company (NYSE:LLY) recently and he didn’t hold back in expressing his support for the company’s CEO and how high his conviction is on the stock. Here’s what he said on the 2^nd of April:

“You don’t sell Lilly. Lilly’s got the solution that may be good for everything from Alzheimer’s to heart disease, kidney failure, liver problems, and right now, weight and diabetes. And that’s at GLP-1, and Lilly got the big lead. David Ricks is a visionary. We stay long that stock.”

“I think that Eli Lilly is probably one of the least tariffed, least dangerous stocks. It does have a high dollar amount, $818, but I remember what Ken Langone told us, he’s the greatest, greatest investor that I’ve ever dealt with. He says, own Eli Lilly, going to a trillion dollars… I am with Ken Langone.”